{"id":"tigecycline-antimicrobial-lock-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Tooth discoloration (with systemic use)"}]},"_chembl":{"chemblId":"CHEMBL376140","moleculeType":"Small molecule","molecularWeight":"585.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a tetracycline-class antimicrobial, tigecycline binds to bacterial ribosomes and blocks translation of mRNA into proteins, effectively halting bacterial growth. When formulated as an antimicrobial-lock solution, it is instilled into central venous catheters to prevent and treat catheter-related bloodstream infections by maintaining high local antibiotic concentrations at the catheter tip.","oneSentence":"Tigecycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:42.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of catheter-related bloodstream infections (CRBSI) in central venous catheters"}]},"trialDetails":[{"nctId":"NCT02040818","phase":"PHASE2, PHASE3","title":"Treatment of Hemodialysis Catheter-Related Bacteremia","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2013-11","conditions":"Hemodialysis Catheter-related Bacteremia","enrollment":""},{"nctId":"NCT01592032","phase":"PHASE4","title":"Concentration of Antimicrobials in Catheter-lock Solutions","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2012-05","conditions":"Catheter-Related Infections, Bacteremia.","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tigecycline: tygacil 50 mg vial.","sodium chloride 0,9% 10 ml vial.","sodium heparin 1%, 5000 IU/5ml."],"phase":"marketed","status":"active","brandName":"Tigecycline antimicrobial-lock solution","genericName":"Tigecycline antimicrobial-lock solution","companyName":"Clinica Universidad de Navarra, Universidad de Navarra","companyId":"clinica-universidad-de-navarra-universidad-de-navarra","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tigecycline is a small molecule inhibitor that works by targeting the bacterial 70S ribosome. It has been studied as an antimicrobial-lock solution for conditions such as catheter-related infections, bacteremia, and hemodialysis catheter-related bacteremia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}